In vivo recovery and safety of human factor VIII product AAFACT® in patients with haemophilia A

Haemophilia

Volumn 9, Issue 2, 2003, Pages 157-163

  Vossebeld, P J M ^a   Tissing, M H ^a   van den Berg, H M ⁱ   Leebeek, F W G ^b   de Goede Bolder, A ^c   Novakova I R O ^d   Gerrits, W B J ^e   Peters, M ^f   Koopman, M M W ^f   Faber, A ^a   Hiemstra, H ^g   Grob, P ^h   Strengers, P F W ^a  

^a CENTRAL LABORATORY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEYENBURG HOSPITAL   (Netherlands)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g Sanquin Plasmaproducten   (Netherlands)

^h PAREXEL INTERNATIONAL   (United States)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bleeding disorder; Factor VIII; Haemophilia; Plasma product; Postmarketing surveillance; Treatment

Indexed keywords

AAFACT; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ACNE CONGLOBATA; AGE; ANTIBODY PRODUCTION; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SAFETY; FEVER; HEADACHE; HEART ARREST; HEMOPHILIA A; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALAISE; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REGISTRATION; STOMACH HEMORRHAGE; TASTE DISORDER; VIRUS TRANSMISSION;

EID: 0037366680     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00730.x     Document Type: Article

References (10)

1. Consensus Hemofilie: Behandeling en verantwoordelijkheid. Results from a consensus meeting at 31 October 1996, Ede, The Netherlands. A publication from CBO, Utrecht, The Netherlands, 1997.
2. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
3. Lee ML. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993; 69: 87.
4. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
5. Giles AR, Verbruggen B, Rivard GE, Teitel, J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
6. Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII in patients with hemophilia. J Pediatr 1992; 121: 816-18.
7. Aronstam A, McLellan DS, Wassef M, Mbatha PS. Effect of height and weight on the in vivo recovery of transfused factor VIII:C. J Clin Pathol 1982; 35: 289-91.
8. Lilleyman JS, Hann IM, Blanchette VS, eds. Reference values. Pediatric Hematology, 2nd edn. London: Churchill Livingstone, 1999: 11.
9. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6.
10. Addiego JE Jr, Gomperts E, Liu S et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.